Reboxetine is a selective noradrenaline reuptake inhibitor--the first in its class

The need for new and better
antidepressants: reboxetine a new option

Dencker SJ

Neuropsychiatry Unit,
Institute of Clinical Neurosciences,
Sahlgrenska University Hospital, Goteborg, Sweden.
Acta Psychiatr Scand Suppl 2000; 402:6-11

ABSTRACT

The selective serotonin reuptake inhibitors (SSRIs) have obtained global attention but have not demonstrated superior efficacy in major depression compared with older tricyclic antidepressants. From a pharmacological viewpoint the noradrenergic system in the brain appears to have a central role in neurotransmitter organization. The importance of noradrenaline in depression is supported by its association with clinical parameters such as vigilance and drive. Reboxetine is a selective noradrenaline reuptake inhibitor--the first in its class to be marketed. In both preclinical and clinical studies reboxetine has been found to be an effective and safe antidepressant. Furthermore, reboxetine restores a patients' social functioning, producing a better quality of remission than fluoxetine.

Back to order (prescription not required)

                    Reboxetine  research / abstracts

        1.   Reboxetine role in antidepressant therapy
        2.   Reboxetine efficacy and tolerability
        3.   Reboxetine clinical pharmacologic profile
         4.   Inhibiting the reuptake of noradrenaline and serotonin
        5.   Reboxetine and depression in the elderly
         6.   Reboxetine with severe major depressive disorder
         7.   Reboxetine clinical efficacy in major depression
        8.   Reboxetine tolerability and safety for major depression
         9.   Reboxetine comparison with fluoxetine
        10   Reboxetine versus fluoxetine, impact on social functioning
        11.  Reboxetine  versus fluoxetine, differential effects
        12.  Reboxetine prevents relapse in major depression
        13   Reboxetine efficacy compared with imipramine
        14.  Noradrenaline reuptake inhibition
        15.  Antidepressants noradrenergic versus serotonergic
        16. Reboxetine in the treatment of bulimia
        17. Reboxetine hemodynamic effects in healthy males
        18. Reboxetine effects of antidepressant therapy
        19. Reboxetine place in antidepressant therapy
        20. Reboxetine stimulant effects in patients with narcolepsy
        21. Reboxetine selective noradrenaline reuptake inhibitor (NARI)

Reboxetine manufacturer's product insert

HOME to order (prescription not required)

Hit Counter